Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents

1. Davies, M.J.
2. Leiter, L.A.
3. Guerci, B.
4. Grunberger, G.
5. Ampudia-Blasco, F.J.
6. Yu, C.
7. Stager, W.
8. Niemoeller, E.
9. Souhami, E.
10. Rosenstock, J.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1111/DOM.12980 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus